Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
8th Mar 202210:21 amRNSHolding(s) in Company
7th Mar 20225:12 pmRNSTransaction in Own Shares
7th Mar 20221:36 pmRNSDirector/PDMR Shareholding
4th Mar 20226:20 pmRNSTransaction in Own Shares
3rd Mar 20225:44 pmRNSTransaction in Own Shares
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM
21st Apr 20217:00 amRNSHikma resumes launch of generic Advair Diskus®
13th Apr 202111:35 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.